Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1992 December; 66(6): 1053–1058.
PMCID: PMC1978042

Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.


The bioreductive cytotoxic agent SR 4233 (1,2,4-benzotriazine 3-amine 1,4-dioxide) has been shown to markedly potentiate the cell killing of mouse tumours when combined with fractionated radiation therapy. Differential metabolism under oxic compared to hypoxic conditions results in SR 4233 exhibiting selective cytotoxicity to hypoxic cells. This is thought to result from the production of a cytotoxic free radical which is generated predominantly in the absence of oxygen. We have examined a way of enhancing the effectiveness of this antitumour agent in vivo by artificially increasing the hypoxic fraction of tumours by hypoxic breathing. Mice are placed in a chamber containing 10% Oxygen 90% Nitrogen for 1 h after each administration of SR 4233. Our results in the SCCVII tumour model indicate that this manoeuvre results in a 10-fold increase in antitumour effectiveness of SR 4233 when administered in a fractionated regime with radiotherapy (8 x 2.5 Gy and 0.08 mmol kg-1), but not when a single treatment regime (1 x 20 Gy and 0.3 mmol kg-1) is used. Mathematical modelling of this effect is used to illustrate this phenomenon and can be used to predict the dependence of this type of therapy on the modification of tumour oxygenation.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Adams GE, Flockhart IR, Smithen CE, Stratford IJ, Wardman P, Watts ME. Electron-affinic sensitization. VII. A correlation between structures, one-electron reduction potentials, and efficiencies of nitroimidazoles as hypoxic cell radiosensitizers. Radiat Res. 1976 Jul;67(1):9–20. [PubMed]
  • Baker MA, Zeman EM, Hirst VK, Brown JM. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 1988 Nov 1;48(21):5947–5952. [PubMed]
  • Brown JM, Koong A. Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst. 1991 Feb 6;83(3):178–185. [PubMed]
  • Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 1990 Dec 15;50(24):7745–7749. [PubMed]
  • Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, Pringle JF. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978 Jun;3:302–306. [PubMed]
  • CHURCHILL-DAVIDSON I, SANGER C, THOMLINSON RH. Oxygenation in radiotherapy. II. Clinical application. Br J Radiol. 1957 Aug;30(356):406–422. [PubMed]
  • Coleman CN. Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst. 1988 May 4;80(5):310–317. [PubMed]
  • Dische S. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys. 1991 Jan;20(1):147–152. [PubMed]
  • Dische S, Anderson PJ, Sealy R, Watson ER. Carcinoma of the cervix--anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol. 1983 Apr;56(664):251–255. [PubMed]
  • Henk JM. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers? Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1339–1341. [PubMed]
  • Hirst DG, Wood PJ. The adaptive response of mouse tumours to anaemia and retransfusion. Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Apr;51(4):597–609. [PubMed]
  • Kennedy KA, Teicher BA, Rockwell S, Sartorelli AC. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol. 1980 Jan 1;29(1):1–8. [PubMed]
  • Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 1984 May;10(5):695–712. [PubMed]
  • Sealy R. Hyperbaric oxygen in the radiation treatment of head and neck cancers. Radiother Oncol. 1991;20 (Suppl 1):75–79. [PubMed]
  • Tannock I, Guttman P. Response of Chinese hamster ovary cells to anticancer drugs under aerobic and hypoxic conditions. Br J Cancer. 1981 Feb;43(2):245–248. [PMC free article] [PubMed]
  • Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990 Jun 1;50(11):3339–3344. [PubMed]
  • Van Putten LM, Kallman RF. Oxygenation status of a transplantable tumor during fractionated radiation therapy. J Natl Cancer Inst. 1968 Mar;40(3):441–451. [PubMed]
  • Withers HR. Biological basis for high-LET radiotherapy. Radiology. 1973 Jul;108(1):131–137. [PubMed]
  • Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1986 Jul;12(7):1239–1242. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK